Physician profile
Mark P Eberhard
NPI 1760945877
$3,971.59
in general payments reported to CMS, 2019-2025
35 companies · $745 in 2025
The $745 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $569 · 2022: $1,233 · 2023: $683 · 2024: $741 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,097.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $495.14 | 2022-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $291.88 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $233.37 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $171.99 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $170.23 | 2021-2025 | Freestyle Libre 3, Octrode |
| Silk Road Medical, INC. | $142.86 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Biohaven Pharmaceutical Holding Company Ltd. | $122.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $105.05 | 2021-2022 | |
| Exact Sciences Corporation | $86.04 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $85.14 | 2022-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.85 | 2022-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $80.25 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.62 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.71 | 2022-2025 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.65 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Mannkind Corporation | $54.27 | 2021-2023 | Afrezza |
| Phathom Pharmaceuticals, INC. | $46.02 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $45.54 | 2023-2024 | Keveyis |
| Pfizer INC. | $43.84 | 2024 | |
| Idorsia Pharmaceuticals US INC | $42.47 | 2022-2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $39.34 | 2022-2023 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $38.95 | 2021-2022 | |
| Verona Pharma, INC. | $34.71 | 2025 | Ohtuvayre |
| Corcept Therapeutics | $32.50 | 2024-2025 | Korlym |
| Amgen INC. | $32.34 | 2025 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $31.37 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $29.66 | 2023-2024 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $28.86 | 2022 | |
| Gilead Sciences, INC. | $22.50 | 2024 | Descovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.64 | 2024 | Caplyta |
| Amarin Pharma, INC. | $17.53 | 2022 | |
| Medtronic, INC. | $17.33 | 2021 | |
| Insulet Corporation | $16.94 | 2024 | Omnipod |
| Grifols USA, LLC | $16.86 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Eberhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.